Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study

Elevated blood pressure was associated with increased Aβ PET accumulation in cognitively unimpaired individuals. Further research is warranted to elucidate potential mechanisms underlying the negative associations between DBP and CSF biomarkers, which do not reflect the typical AD molecular signature. These findings highlight the relevance of high blood pressure as a potential risk factor for cognitive decline.

Authors

Institutions

Publication Details

Journal
The Journal of Prevention of Alzheimer s Disease
Published
2025-08-11
DOI
https://doi.org/10.1016/j.tjpad.2025.100304
Citations
5
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
7.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study

Abril Martínez-Velasco, David Vállez García, Gonzalo Sánchez‐Benavides, Kaj Blennow et al.
5 citations
The Journal of Prevention of Alzheimer s Disease
Dementia and Cognitive Impairment Research
7.36
article

Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study

Abril Martínez-Velasco, David Vállez García, Gonzalo Sánchez‐Benavides, Kaj Blennow, Mahnaz Shekari, Juan Domingo Gispert, Maríateresa Buongiorno, Oriol Grau‐Rivera, Gwendlyn Kollmorgen, Marc Suárez‐Calvet, Carolina Minguillón, Alejandro de la Sierra, Clara Quijano‐Rubio, Henrik Zetterberg, Mariona Osset-Malla
article en
5 citations

Abstract

Elevated blood pressure was associated with increased Aβ PET accumulation in cognitively unimpaired individuals. Further research is warranted to elucidate potential mechanisms underlying the negative associations between DBP and CSF biomarkers, which do not reflect the typical AD molecular signature. These findings highlight the relevance of high blood pressure as a potential risk factor for cognitive decline.

The Journal of Prevention of Alzheimer s DiseaseVol. 12(10)
Roche (Switzerland) (CH), Sahlgrenska University Hospital (SE), Roche Pharma AG (Germany) (DE), University Hospital Mútua de Terrassa (ES), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES), Pasqual Maragall Foundation (ES), UK Dementia Research Institute (GB), Barcelonaβeta Brain Research Center (ES), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (ES), University College London (GB)
Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, European Federation of Pharmaceutical Industries and Associations, Ministerio de Ciencia, Innovación y Universidades, National Institute for Health and Care Research, University College London, European Commission, Hjärnfonden, Vetenskapsrådet, Ministerio de Ciencia e Innovación, UK Dementia Research Institute, Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona, HORIZON EUROPE Framework Programme, Instituto de Salud Carlos III, Agencia Estatal de Investigación
Good health and well-being
Openalex Percentile: Top 3%
Dementia and Cognitive Impairment Research
7.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.